Etaracizumab, CAS [[892553-42-3]]

Produktübersicht

• Artikelname: Etaracizumab, CAS [[892553-42-3]]
• Artikelnummer: MCE-HY-P99291
• Hersteller Artikelnummer: HY-P99291
• Alternativnummer: MCE-HY-P99291-25MG,MCE-HY-P99291-10MG,MCE-HY-P99291-1MG,MCE-HY-P99291-5MG
• Hersteller: MedchemExpress
• Kategorie: Antikörper
• Alternative Synonym: LM609, MEDI-522

Produktbeschreibung

Etaracizumab (LM 609) is an alphavbeta3 integrin IgG mAb. Etaracizumab is developed to target alphavbeta3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofalphavbeta3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001)[1][2][3][4][5].

Produkteigenschaften

• Molekulargewicht: (146.64 kDa)
• Reinheit: 99.81
• CAS Nummer: [892553-42-3]
• Target-Kategorie: Akt,Apoptosis,Integrin

Anwendungsbeschreibung

• Anwendungsbeschreibung: MCE Product type: Inhibitory Antibodies